Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Authors
Cunningham, DHawkes, E
Jack, A
Qian, W
Smith, P
Mouncey, P
Pocock, C
Ardeshna, K
Radford, John A
McMillan, A
Davies, J
Turner, D
Kruger, A
Johnson, P
Gambell, J
Linch, D
Affiliation
Royal Marsden NHS Foundation Trust, London and Surrey, UK. david.cunningham@rmh.nhs.ukIssue Date
2013-05-25
Metadata
Show full item recordAbstract
Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. We investigated whether this survival benefit from dose intensification persists in the presence of rituximab (R-CHOP) in all age groups.Citation
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. 2013, 381 (9880):1817-26 LancetJournal
LancetDOI
10.1016/S0140-6736(13)60313-XPubMed ID
23615461Type
ArticleLanguage
enISSN
1474-547Xae974a485f413a2113503eed53cd6c53
10.1016/S0140-6736(13)60313-X